Joseph G. Pressey · Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis
Follow
Article1 min read·Published Mar 2021Older

Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Mar 2021 · 1 min read

In brief

In brief

This preclinical study demonstrates that EYA3, a protein upregulated by the EWSR1/FLI1 fusion in Ewing sarcoma, promotes tumor growth through VEGFA-mediated angiogenesis and DNA damage repair. Both genetic knockout and pharmacologic inhibition with Benzarone reduced tumor growth in xenograft models, validating EYA3 tyrosine phosphatase as a potential therapeutic target.

Written by the GCMD Library team from the article.

Joseph G. Pressey

EWSR1/FLI1, the most common fusion gene in Ewing sarcoma, upregulates expression of the Eyes Absent 3 (EYA3) transactivator-phosphatase protein. The purpose of this study was to investigate molecular and cellular mechanisms through which EYA3 might promote Ewing sarcoma tumor growth and to determine whether the EYA3 tyrosine phosphatase activity represents a viable therapeutic target. We used genetic and pharmacologic modulation of EYA3 in cell line-based xenografts to examine how loss of EYA3 tyrosine phosphatase activity affects tumor growth and angiogenesis. Molecular mechanisms were evaluated in vivo and in vitro through analyses of tumor tissue and multicellular tumor spheroids. Our results show that both loss of EYA3 in Ewing sarcoma cells and pharmacologic inhibition of the EYA3 tyrosine phosphatase activity inhibit tumor growth and tumor angiogenesis. EYA3 regulates levels of VEGFA in Ewing tumors, as well as promoting DNA damage repair and survival of Ewing sarcoma tumor cells. Target engagement is demonstrated in tumor tissue through elevated levels of the EYA3 substrate H2AX-pY142 upon loss of EYA3 or with Benzarone treatment. The efficacy of EYA3 tyrosine phosphatase inhibition in attenuating tumor growth and angiogenesis is corroborated in an Ewing sarcoma patient-derived tumor xenograft. Together, the results presented here validate EYA3 as a target for the development of novel Ewing sarcoma therapeutic strategies, and set the stage for evaluating the efficacy o

Statements in this article

  1. EWSR1/FLI1, the most common fusion gene in Ewing sarcoma, upregulates expression of the Eyes Absent 3 (EYA3) transactivator-phosphatase protein.

    Established
  2. Loss of EYA3 in Ewing sarcoma cells inhibits tumor growth and tumor angiogenesis.

    Research
  3. Pharmacologic inhibition of the EYA3 tyrosine phosphatase activity inhibits tumor growth and tumor angiogenesis.

    Research
  4. EYA3 regulates levels of VEGFA in Ewing tumors.

    Research
  5. EYA3 promotes DNA damage repair and survival of Ewing sarcoma tumor cells.

    Research
  6. Target engagement is demonstrated in tumor tissue through elevated levels of the EYA3 substrate H2AX-pY142 upon loss of EYA3 or with Benzarone treatment.

    Research
  7. The efficacy of EYA3 tyrosine phosphatase inhibition in attenuating tumor growth and angiogenesis is corroborated in an Ewing sarcoma patient-derived tumor xenograft.

    Research

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.